Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)

NCT00427362 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00427362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00427362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)
Lead sponsor
Abbott
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
Not reported
Enrollment
127 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis